ImmunityBio (NASDAQ:IBRX) Shares Gap Up – Here’s Why

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $7.76, but opened at $8.42. ImmunityBio shares last traded at $8.1140, with a volume of 8,016,909 shares trading hands.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: The FDA accepted ImmunityBio’s supplemental BLA for ANKTIVA plus BCG, moving the bladder cancer expansion application forward and assigning a PDUFA date of January 6, 2027. Article Title
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and set a $15 price target, signaling bullish analyst sentiment toward IBRX. Article Title
• Positive Sentiment: ImmunityBio secured five U.S. patents for Anktiva in bladder cancer, strengthening franchise protection through 2035. Article Title
• Neutral Sentiment: The company continues to attract investor attention around a securities class action deadline tied to prior FDA-related allegations, but these notices are largely legal reminders rather than new operational developments. Article Title
• Negative Sentiment: Ongoing class-action claims related to FDA warning concerns over Anktiva’s advertising add legal overhang and could pressure sentiment. Article Title

Wall Street Analyst Weigh In

A number of research firms have issued reports on IBRX. BTIG Research set a $12.00 target price on shares of ImmunityBio in a research report on Friday, May 8th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of ImmunityBio in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Tuesday, May 5th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $14.20.

ImmunityBio Trading Up 7.5%

The company has a market cap of $8.73 billion, a PE ratio of -9.77 and a beta of 0.02. The business’s 50-day simple moving average is $7.78 and its 200-day simple moving average is $5.49.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The firm had revenue of $44.21 million for the quarter, compared to the consensus estimate of $43.07 million. On average, research analysts predict that ImmunityBio, Inc. will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling at ImmunityBio

In other news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Barry J. Simon sold 165,000 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the transaction, the director owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This trade represents a 5.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 275,000 shares of company stock worth $2,934,500. 69.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Western Wealth Management LLC acquired a new position in shares of ImmunityBio during the 1st quarter worth $44,000. Geneos Wealth Management Inc. increased its stake in shares of ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock worth $44,000 after purchasing an additional 4,907 shares during the last quarter. Archer Investment Corp increased its stake in shares of ImmunityBio by 67.1% during the 1st quarter. Archer Investment Corp now owns 5,872 shares of the company’s stock worth $45,000 after purchasing an additional 2,358 shares during the last quarter. Slow Capital Inc. acquired a new position in shares of ImmunityBio during the 3rd quarter worth $25,000. Finally, Hodges Capital Management Inc. acquired a new position in shares of ImmunityBio during the 1st quarter worth $77,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.